Cutibacterium acnes cellular components (C. acnes components)

Cutibacterium acnes (formerly Propionibacterium acnes) is a Gram-positive, anaerobic bacterium that is a major constituent of the human skin microbiome, particularly within the pilosebaceous unit (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240639/). While it typically exists as a commensal, its proliferation and metabolic activity are central to the pathogenesis of acne vulgaris, where it induces inflammation through the secretion of proinflammatory mediators and enzymes (https://pubmed.ncbi.nlm.nih.gov/29359387/). Therapeutic strategies targeting C. acnes cellular components aim to reduce bacterial density and the resulting inflammatory cascade. These targets include the bacterial ribosome (inhibited by macrolides and tetracyclines), the cell wall, and various metabolic pathways (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224593/). Effective management often involves topical or systemic antimicrobial agents, though the increasing prevalence of antibiotic-resistant C. acnes strains poses a significant challenge to long-term treatment efficacy (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436557/). Beyond acne, C. acnes is also implicated in opportunistic infections following surgery or in the presence of medical devices (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541634/). While C. acnes is the primary focus, other members of the skin flora, such as Staphylococcus epidermidis, also interact with these therapeutic agents, sometimes leading to broader microbiome shifts (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551880/).

Other names

Propionibacterium acnes componentsSkin flora bacterial componentsAcne-associated bacterial targets

Drugs targeting these components act by inhibiting bacterial protein synthesis via the 30S or 50S ribosomal subunits, disrupting the bacterial cell wall through oxidative stress, or inhibiting DNA replication and metabolic pathways.